Details of the Drug Combination

General Information of Drug Combination (ID: DCEMT7D)

Drug Combination Name
Daclatasvir INX-189
Indication
Disease Entry Status REF
Hepatitis C Virus Phase 1 [1]
Component Drugs Daclatasvir   DMSFK9V INX-189   DMSTJ6Q
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Daclatasvir
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Approved [2]
Daclatasvir Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Hepatitis C virus Non-structural 5A (HCV NS5A) TTCJ2X8 POLG_HCV1 Inhibitor [4]
------------------------------------------------------------------------------------
Daclatasvir Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]
------------------------------------------------------------------------------------
Daclatasvir Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [6]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of INX-189
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 2 [3]
INX-189 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) TTMVBWH POLG_HCV1 Inhibitor [7]
------------------------------------------------------------------------------------
INX-189 Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
DNA-directed RNA polymerase, mitochondrial (POLRMT) OT5Q8ZUJ RPOM_HUMAN Decreases Expression [8]
Cytochrome c oxidase subunit 2 (COX2) OTTMVBJJ COX2_HUMAN Decreases Expression [8]
NADH-ubiquinone oxidoreductase chain 1 (ND1) OTCLGIXV NU1M_HUMAN Decreases Expression [8]
NADH-ubiquinone oxidoreductase chain 5 (ND5) OT45LW1K NU5M_HUMAN Decreases Expression [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01629732) Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 ClinicalTrials.gov (NCT01425970) Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin. U.S. National Institutes of Health.
4 2011 Pipeline of Bristol-Myers Squibb.
5 Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
6 Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
7 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
8 Effects of BMS-986094, a Guanosine Nucleotide Analogue, on Mitochondrial DNA Synthesis and Function. Toxicol Sci. 2016 Oct;153(2):396-408. doi: 10.1093/toxsci/kfw135. Epub 2016 Jul 27.